Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3378383 | 0.84 | — | — | |
| SCHEMBL3371415 | 0.84 | — | — | |
| SCHEMBL13166246 | 0.82 | CES1 (0.30) | — | |
| Hydrochloric Acid SCHEMBL17802194 | 0.80 | — | — | |
| SCHEMBL4400701 | 0.78 | CYP2D6 (0.30) | — | |
| SCHEMBL13069216 | 0.76 | CES1 (0.31) | — | |
| SCHEMBL15153952 | 0.72 | — | — | |
| SCHEMBL761768 | 0.71 | CETP (0.32) | CETP | |
| SCHEMBL11928239 | 0.67 | — | — | |
| SCHEMBL2371656 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210053962-A1 | NOVEL PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2021-02-25 | — | — | US | disclosed |
| US-20120277279-A1 | Non-Steroidal Glucocorticoid Inhibitors and Their Use in Treating Inflammation, Allergy and Auto-Immune Conditions | GLAXO GROUP LIMITED | 2012-11-01 | — | — | US | disclosed |
| US-20120277279-A1 | Non-Steroidal Glucocorticoid Inhibitors and Their Use in Treating Inflammation, Allergy and Auto-Immune Conditions | GLAXO GROUP LIMITED | 2012-11-01 | — | — | US | disclosed |
| US-20120277279-A1 | Non-Steroidal Glucocorticoid Inhibitors and Their Use in Treating Inflammation, Allergy and Auto-Immune Conditions | GLAXO GROUP LIMITED | 2012-11-01 | — | — | US | disclosed |
| US-8247377-B2 | Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions | GLAXO GROUP LIMITED (GB) | 2012-08-21 | — | — | US | disclosed |
| US-8247377-B2 | Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions | GLAXO GROUP LIMITED (GB) | 2012-08-21 | — | — | US | disclosed |
| US-8247377-B2 | Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions | GLAXO GROUP LIMITED (GB) | 2012-08-21 | — | — | US | disclosed |
| EP-2029549-B1 | PHENYL-PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORICOID RECEPTOR LIGANDS | GLAXO GROUP LTD (GB) | 2010-11-10 | — | — | EP | disclosed |
| EP-2029549-B1 | PHENYL-PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORICOID RECEPTOR LIGANDS | GLAXO GROUP LTD (GB) | 2010-11-10 | — | — | EP | disclosed |
| US-20100234441-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| US-20100234441-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| US-20100234441-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| EP-2029549-A2 | PHENYL-PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORICOID RECEPTOR LIGANDS | Glaxo Group Limited (GB) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007144327-A2 | PHENYL-PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007144327-A2 | PHENYL-PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234441-A1 | NOVEL COMPOUNDS | LTB4R2, TSLP, LTB4R | CETP 303/4885 |
| US-20210053962-A1 | NOVEL PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A2, GUCY1B1, GUCY1B2 | CETP 2518/4885 |
| US-20120277279-A1 | Non-Steroidal Glucocorticoid Inhibitors and Their Use in Treating Inflammation, Allergy and Auto-Immune Conditions | NR3C1, SERPINA6, PTGS1 | CETP 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.